ArticleEndocrine2025
The association between serum uric acid to high density lipoprotein ratio and cardiometabolic-related risk in adults with obesity.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe uric acid (UA) to high density lipoproteins (HDL) ratio (UHR) has recently emerged as a new effective biomarker for inflammation and cardiometabolic diseases. However, the relationship between UHR and the metabolic syndrome and its components and other cardiometabolic parameters in individuals with obesity remains to be further investigated.
aimTo evaluate UHR levels in participants with obesity, as well correlation of UHR with other cardiometabolic risk factors. Moreover, the predictive value of UHR for insulin resistance, metabolic syndrome and visceral adiposity (estimated by using waist circumference) was evaluated, also with respect to UHR components (UA and HDL alone).
methodsParticipants were enrolled from the Center of Obesity and Work, Occupational Health Unit of Clinica del Lavoro "L. Devoto", Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan (Italy) and divided into two groups according to body mass index (BMI) values; controls (when BMI < 30 kg/m
resultsA total of 1743 (1268 females, mean age 52 ± 14 years) was enrolled in the study. Multiple logistic regression analysis indicated a significant association between obesity and UHR (odds ratio (95% confidence intervals) p value; 1.1 (1-1.1) < 0.01) after adjustment for different biomarkers of cardiometabolic risk. The area under the ROC curve (AUC) of UHR was significantly larger compared with the use of HDL or UA alone for insulin resistance (0.73, 0.3 and 0.67, respectively), metabolic syndrome (0.77, 0.26 and 0.69, respectively) and waist circumference (0.65, 0.37 and 0.62, respectively).
conclusionElevated UHR, better than UA or HDL alone, demonstrates a significant correlation with obesity and cardiometabolic parameters, so it could be used as a potential indicator of cardiometabolic risk in this clinical setting.
Indexed as
Identifiers
40397365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.